Sufianov Albert, Begliarzade Sema, Ilyasova Tatiana, Liang Yanchao, Beylerli Ozal
Federal Center of Neurosurgery, Tyumen, Russia.
Department of Neurosurgery, Sechenov First Moscow State Medical University (Sechenov University), Moscow, Russia.
Noncoding RNA Res. 2022 Jul 6;7(3):171-177. doi: 10.1016/j.ncrna.2022.07.001. eCollection 2022 Sep.
Gliomas are invasive brain tumors characterized by high rates of recurrence and mortality. Glioblastoma (GBM), a grade IV brain tumor, is known for its heterogenicity and its resistance to the current treatment regimen. MicroRNA (miRNAs) are small non-coding sequences of RNA that regulate and influence the expression of multiple genes. The detection of certain types of micro-RNA in tissues and blood serum can be used for diagnosis and prognosis, including the response of a particular patient to therapy. The purpose of this review is to analyze studies and experimental results concerning changes in microRNA expression profiles characteristic of gliomas. Furthermore, miRNAs also contribute to autophagy at multiple stages. In this review, we summarize the functions of miRNAs in GBM pathways linked to dysregulation of cell cycle control, apoptosis and resistance to treatment, and the possible use of miRNAs in clinical settings as treatment and prediction biomarkers.
胶质瘤是侵袭性脑肿瘤,其特征是高复发率和死亡率。胶质母细胞瘤(GBM)是一种IV级脑肿瘤,以其异质性和对当前治疗方案的耐药性而闻名。微小RNA(miRNA)是RNA的小非编码序列,可调节和影响多个基因的表达。在组织和血清中检测某些类型的微小RNA可用于诊断和预后评估,包括特定患者对治疗的反应。本综述的目的是分析有关胶质瘤特征性微小RNA表达谱变化的研究和实验结果。此外,miRNA在多个阶段也参与自噬。在本综述中,我们总结了miRNA在与细胞周期控制失调、凋亡和治疗耐药相关的GBM通路中的功能,以及miRNA在临床环境中作为治疗和预测生物标志物的可能用途。